Navigation Links
Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
Date:5/20/2008

- Data being presented today at Digestive Disease Week -

CAMBRIDGE, Mass. and NEW YORK, May 20 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX) today announced the presentation of data from a Phase 2b randomized, double-blind, placebo-controlled study assessing the safety and efficacy of linaclotide in patients with chronic constipation (CC). Analysis of these data indicate that linaclotide met its primary endpoint. The study results are being presented today at the Digestive Disease Week conference in San Diego by Anthony Lembo, M.D. of the Beth Israel Deaconess Medical Center in Boston.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

In the four-week study, once-daily doses of linaclotide -- 75 mcg, 150 mcg, 300 mcg, or 600 mcg -- were compared to placebo. The primary endpoint was the change from pre-treatment in weekly spontaneous bowel movement (SBM) frequency. During the two-week pre-treatment period, the mean baseline weekly SBM frequency rate for the intent-to-treat (ITT) population (n = 307) across all treatment groups was 2.3. Patients in the ITT population who received once-daily dosing of linaclotide demonstrated a statistically significant change in weekly SBM frequency of 2.6 (75 mcg, p < 0.05), 3.3 (150 mcg, p < 0.01), 3.6 (300 mcg, p < 0.001), and 4.3 (600 mcg, p < 0.001) compared to 1.5 for patients receiving placebo. Increases in SBM frequency were dose-related. At all doses above 75 mcg, linaclotide-treated patients also experienced statistically significant improvements in complete spontaneous bowel movement (CSBM) frequ
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
2. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
3. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
5. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
6. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
7. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
8. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
9. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
10. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
11. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... - Health Canada is working with the Canadian manufacturers ... information regarding the risk of serious cardiovascular side effects ... used at high doses (at or above 2400 mg/day). ... Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) ... inflammation. The majority of ibuprofen products in ...
(Date:4/23/2015)... 2015 Nektar Therapeutics (Nasdaq: NKTR ) will ... 31, 2015 on Thursday, April 30, 2015, after the close ... chief executive officer, will host a conference call to review ... Pacific Time (PT). The press release and ... accessed through a link that is posted on the home ...
(Date:4/23/2015)... 23, 2015 Surna, Inc. (OTCQB: SRNA), a ... art equipment and systems for controlled environment agriculture ... cultivation, will host a shareholder conference call to ... at 4:15 PM Eastern Standard Time/1:15 PM Pacific ... will be listen-in only, but will include a ...
Breaking Medicine Technology:Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2Surna, Inc. Announces Shareholder Conference Call 2Surna, Inc. Announces Shareholder Conference Call 3
...  Results from the combined analysis of two European ... 3rd European Lung Cancer Conference in Geneva, Switzerland. ... samples from advanced non-squamous non-small cell lung cancer ... plus erlotinib.  Results showed that the VeriStrat test ...
... (NASDAQ: STAA ), the leading developer, manufacturer and ... that the total number of its Visian® ICL implants in ... have been the Visian Toric ICL which is approved in ... of the U.S. The Company will highlight the benefits of ...
Cached Medicine Technology:VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 2VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 3STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 2STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 3STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 4STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 5
(Date:4/26/2015)... In an article published last month in Ergonomics ... occurring during the use of handheld electronic devices such as ... use of a tablet increases mechanical demand on neck muscles ... than when the neck is in a neutral position. Perhaps ... out the potential hazards of overuse of mobile technology may ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 MidSouth ... grow throughout the Southeast. MidSouth Pain Treatment Center is ... in Cordova, Southaven, Oxford and Jackson, two ambulatory surgery ... in the Southaven and Cordova locations. , Dr. ... ”I went into medicine to help people, and when ...
(Date:4/25/2015)... Avid Collector Andrew Hawley from Vintage Rock ... Coliseum concert posters. The concert was held on 12 ... American Tour. , According to Hawley, “The poster ... Maryland. This poster blank was used to advertise the ... uses garish lettering and colors on this boxing style ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 In the ... twelve and above needed treatment for an illicit ... the Substance Abuse and Mental Health Services Administration’s Survey ... Beyond these alarming numbers are harrowing stories of men ... substance abuse . David H. Kerr , founder ...
(Date:4/25/2015)... 25, 2015 By definition, a CIO’s responsibility ... the enterprise relying on their judgement and expertise to keep ... according to an article published in National Mortgage News ... be doing a disservice to their responsibilities by focusing too ... t’s are crossed when it comes to company policy and ...
Breaking Medicine News(10 mins):Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Growing Pains for MidSouth Pain Treatment Center 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5
... CLEVELAND, Sept. 6 Cleveland Clinic Press,( ... ( http://www.clevelandclinic.org/ ), has just released "Write ... Journal Writing" by Dr.,Sheppard B. Kominars ( ... powerful insights and techniques for personal transformation ...
... Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) today filed ... Report on Form 10-K. The,filing of Par,s Form 10-K ... in restating its consolidated financial statements for certain,prior periods, ... file its,Form 10-Q for the first and second quarters ...
... ANA, Calif., Sept. 6 Responding to increasing,needs ... in the number of people it,serves, Regional Center ... expand and improve the support it provides to ... 1. Special Education Advocacy. RCOC launched a program ...
... the patient real benefit, too , THURSDAY, Sept. 6 ... disease report better physical health if they participate in ... the health of spouse caregivers through counseling and support ... who are in poor health are more likely to ...
... Richard Trumka to Keynote Canadian, British, Australian RNs Describe ... ... Emotional September 11th Rally With a,Plea for Politicians to Focus ... 6 The California Nurses,Association/National Nurses Organizing Committee will convene ...
... consumers ... and business owners in the U.S., HOUSTON, Sept. 6 ... or partially insured consumers and,business owners substantial savings on healthcare, ... Insurance,Brokers, Inc. (IGIB). Based in Chula Vista, CA, IGIB is ...
Cached Medicine News:Health News:Cleveland Clinic Press Releases Journal-Writing Book 'Write for Life: Healing Body, Mind, and Spirit Through Journal Writing' by Sheppard B. Kominars, Ph.D. 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 3Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 4Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 5Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 6Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 7Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 8Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 9Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 10Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 11Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 12Health News:Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs 2Health News:Counseling Boosts Alzheimer's Caregivers' Health 2Health News:Hundreds of RNs from Across U.S. and World to Join California Nurses Association/NNOC National Convention 2Health News:International Gateway Insurance Brokers Partners With MEDILINQ 2Health News:International Gateway Insurance Brokers Partners With MEDILINQ 3
... Allowing your patients to focus ... between the way the eyes ... vision enhancement to a remarkable ... restore your patients vision to ...
... lenses are manufactured using the ... Perspex CQ UV PMMA material ... and single piece lenses. Unioptic ... both nonphaco and phaco styles. ...
Optical implants for the replacement of the human crystalline lens in the visual correction of aphakia....
1% Sodium Hyaluronate, 10mg/mL, sterile opthalmic injection...
Medicine Products: